Regional differences in treatment and outcome in non-small cell lung cancer: A population-based study (Sweden)
Introduction
Approximately 80% of new lung cancer cases are of the non-small cell type (NSCLC) with a 5-year survival of 10–18% [1]. Of these patients, about 50% present with locally advanced or metastatic disease. Until recently, surgical resection was the only therapeutic modality with a curative potential in NSCLC [2]. Results from earlier studies indicate that chemotherapy can offer patients with advanced disease improvements in quality of life and survival compared with best supportive treatment. Recent findings, however, indicate that intensive chemotherapy may entail substantial survival benefits in patients of all ages with advanced disease [3], [4], [5].
In Sweden, uniform recommendations for diagnosis and treatment of lung cancer have been endorsed since 1995. These guidelines were revised in 1999–2000, recommending intensified activity for early detection of lung cancer and increased use of chemotherapy in advanced disease [3], [6]. International guidelines continuously evolve following the introduction of new cytotoxic regimens with lesser toxicity and a greater potential to offer palliation and prolonged survival [7], [8]. Few studies to date have examined whether adherence to guidelines translates into improved survival.
The present study examines the management of patients with NSCLC in relation to guidelines in seven counties in Central Sweden. Firstly, we examined time trends and regional differences in treatment intensity for NSCLC. Secondly, we investigated whether any differences in treatment of NSCLC were associated with differences in survival.
Section snippets
Patients and data collection
For the purpose of the present study, 4791 patients with a diagnosis of a primary NSCLC between January 1st 1995 and December 31st 2003, were identified in the Lung Cancer Register (LCR) of Central Sweden. This clinical database started in 1995, covering seven counties with about two million inhabitants representing 21% of the Swedish population. The composition of the population of Central Sweden has a mix of urban and rural inhabitants similar to that of Sweden as a whole. During the period
Results
Of all NSCLC patients, 2587 were men (mean age 69.2 years; range 23–95) and 1758 were women (mean age 66.3 years; range 26–92). The distribution of demographic characteristics of the patients, including smoking history, was very similar between the county centres (Table 1). The lung cancer diagnosis was verified with cytology or histopathology in more than 95% of cases in all counties but two (E and G county had 92% and 88% respectively).
The two most common histopathological tumour types were
Discussion
In this population-based clinical database, comprising all incident cases of NSCLC recorded in Central Sweden over 9-year-period, we found evidence of a wide variation of treatment strategies between county centres, despite consensus management guidelines for lung cancer. In the reference county centre, 83% of patients received any kind of treatment specifically directed towards lung cancer compared with a range of 59–71% for patients managed in the other centres. However, over time the
Contributors
All contributors took part in the conception and design of the study in the acquisition of data or statistical analyses, interpretation of data, and writing and revision of the report.
Conflict of interest
Part of the time of the study, Mats Lambe was employed by AstraZeneca. All other authors declare no conflicts of interest.
Acknowledgements
This study was supported by the Swedish Cancer Society and an unrestricted grant from AstraZeneca.
References (30)
Revisions in the International System for Staging Lung Cancer
Chest
(1997)- et al.
Who gets chemotherapy for metastatic lung cancer?
Chest
(2000) - et al.
Chemotherapeutic management of stage IV non-small cell lung cancer
Chest
(2003) - et al.
Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy
Lung Cancer
(1999) - et al.
Survival in primary lung cancer potentially cured by operation: influence of tumor stage and clinical characteristics
Ann Thorac Surg
(2003) - et al.
Surgical resection for lung cancer in the octogenarian
Chest
(2004) - et al.
Prevalence of comorbidity in lung cancer patients and its relationship with lung cancer in Europe
Lung Cancer
(1998) - et al.
Variation in survival of patients with lung cancer in Europe, 1985–1989
Eur J Cancer
(1998) - et al.
Influence of age, comorbidity and performance status on the choice of treatment for patients with non-small cell lung cancer; results of a population-based study
Lung Cancer
(2004) - et al.
Management and survival of patients with lung cancer in Scotland diagnosed in 1995: results of a national population based study
Thorax
(2001)
Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-medicare
J Clin Oncol
Vårdprogram för lung cancer
Applied logistic regression
Cited by (42)
Utilisation of radiotherapy in lung cancer: A scoping narrative literature review with a focus on the introduction of evidence-based therapeutic approaches in Europe
2024, Clinical and Translational Radiation OncologyNeuroendocrine Tumors of the Lung Other Than Small Cell Lung Cancer
2018, IASLC Thoracic OncologySocial determinants and lung cancer
2017, Revue des Maladies Respiratoires ActualitesSurgical Management of Advanced Non-Small Cell Lung Cancer Is Decreasing But Is Associated With Improved Survival
2016, Annals of Thoracic SurgeryCitation Excerpt :In a survey of primary care physicians, Wassenaar and colleagues [17] found significant differences in referral patterns and a lack of knowledge regarding treatment options and outcomes among in the primary care community regarding the benefits of treatment of NSCLC [17]. In a Swedish study of treatment trends of all stages of NSCLC, 33.4% of patients underwent no treatment, and there were significant differences in treatment trends based on region of treatment [18]. These investigators observed that increasing age was a significant predictor of not receiving treatment.